From Screening Workflow to Shelf: What an ODM/OEM Partner Actually Gets from Vecura

NYB Vecura | 04 August 2026

The Market Is Real. The Gap Is Execution.

A brand walks in with a trend deck, a price point, and a launch date. What they don't have is proof the ingredient works, clarity on what they're legally allowed to claim, or confidence that the supplier's story holds up. In an ODM/OEM setting, all three of those gaps become the manufacturer's problem too — they can't formulate against an unverified claim or source from a supplier whose paperwork doesn't match their marketing. Answering those questions the old way — literature reviews, regulatory digging, supplier vetting — takes weeks, and by the time you're done, the launch window has moved. That gap, between "promising market" and "sellable, defensible product," is where timelines usually die.

Vecura closes it. It does the homework: grading the evidence, mapping what each market lets you claim, checking supplier facts against supplier marketing — and turns weeks into days. It doesn't replace your formulators, regulatory team, or ODM/OEM partner; it gives them a head start, arriving at the manufacturer's door already vetted instead of half-built.

We already ran this workflow on multiple supplement categories. Here, we apply it to a different category — collagen-led beauty-from-within — to show it holds up regardless of product. You'll see the seven things Vecura delivers at each stage, how they map onto a real build-to-launch timeline, and exactly where Vecura's job ends and your ODM/OEM partner's begins.

What Vecura Actually Does: Seven Use Cases Across the Workflow

This is the core of the platform. Each use case below is a discrete, deliverable-producing step where VEcura does work a partner would otherwise do slowly, expensively, or not at all. The category examples are beauty-from-within; the use cases transfer to any vertical.

Use Case 1 — Evidence-Graded Ingredient Screening

What it is: Every candidate ingredient scored against the published human evidence — RCT quality, dose, effect size, population — and graded, not just listed.

Beauty example: VERISOL collagen peptides screen in on two strong RCTs (69 women, +elasticity [44]; 114 women, −20% eye-wrinkle volume, procollagen I +65% [45]). A bacterial ceramide screens mixed — hydration improved, but no TEWL or viscoelasticity effect [27] — so it gets flagged, not sold. 

Core value: Weeks of literature review compressed to days; mixed results surfaced instead of hidden, so partners don't build claims on ingredients that only half-work.

Use Case 2 — Claim-Legality Mapping per Market

What it is: For each ingredient–claim pair, a map of what can legally be said in each target market, built from the actual regulatory record. 

Beauty example: The same VERISOL evidence was rejected by EFSA (refused via Reg. (EU) No 1154/2014 [9, 10]) yet granted a Foods with Function Claims notification in Japan ("maintain skin elasticity," 2.5 g/day [19, 20]). Same molecule, same data, opposite outcomes. 

Core value: Partners learn what they can say — and where — before committing tooling, MOQs, or label copy.

Use Case 3 — Formulation Direction Design

What it is: Evidence-anchored formulation options with doses tied to the RCTs and the claim map, not to marketing convention. 

Beauty example: Three directions — Dermal Structure (collagen 2.5 g + vit C [44, 45, 36]), Hydration & Barrier (sodium hyaluronate 120 mg + ceramides [39, 23, 25]), UV Resilience (astaxanthin 2 mg + collagen 3 g [33]). 

Core value: A starting point for partner R&D grounded in published doses, with dose–claim dependencies made explicit.

Use Case 4 — Regulatory Route Identification

What it is: The specific filing route per market, with the constraint that makes or breaks it. Beauty example: Japan FFC (operator-responsible claims, no pre-evaluation [17, 18]; 6,606 notifications through Jan 2023 [22]); Korea MFDS individually-recognized ingredients (low-MW collagen, 1 g/day [49]); US structure/function (substantiation + 30-day notification + disclaimer; disease claim = drug [65, 170]); EU nutrient-claim scaffold (vitamin C [36], biotin [69], zinc [74]) — with the ASA/Imedeen upheld-complaint limit on overreach [37]. 

Core value: The regulatory archaeology — which route, which constraint, which precedent — done in days. Boundary: regulatory professionals file; Vecura flags and sources.

Use Case 5 — Supplier & Sourcing Intelligence

What it is: Cost, certification, and positioning data on input materials, with marketing claims separated from evidence. 

Beauty example: Marine collagen runs 2–4x bovine cost [55, 56] and is defensible on positioning (84% consumer preference [58]; MSC-certified supply [57]) — but the ubiquitous "1.5x more bioavailable" claim is the least-examined line in UK collagen marketing [56].

Core value: Partners price and position on verified facts, not on supplier decks.

Use Case 6 — QC Specification Rationale

What it is: The why behind the QC spec — which tests matter for this ingredient and why. Beauty example: Heavy-metal panels for marine collagen (arsenic most abundant, no product over EU limits, high brand variability [76]); DNA barcoding for species authentication, because protein-based tests fail on hydrolyzed collagen [77]. 

Core value: An ODM partner that can promise DNA-verified species and published heavy-metal panels has a sales argument competitors can't copy cheaply.

Use Case 7 — Honest Category Framing

What it is: Plain-language truth about what a category actually is, for partners about to commit capital to it.

Beauty example: "Vegan collagen" is three different things — precursor boosters, marketing fluff (plants can't make hydroxyproline [63]), or true precision-fermentation collagen (FDA GRAS "no questions" [59]). Most products sold as "vegan collagen" are bucket one.

Core value: Partners pitch honestly and avoid the claims that unravel under scrutiny.

Phase A — Decide Direction

Business orientation first, then evidence-graded screening (Use Case 1), then formulation directions (Use Case 3). The screening logic here is claim-first, because the category is claim-constrained — the inverse of the mechanism-first logic we used for sleep. The workflow adapts; the rigor doesn't.

Phase B — Get Ready to Build

Regulatory and regional readiness (Use Cases 2 and 4), then supplier and QC landscape (Use Cases 5 and 6). This is the phase brands most often skip and where partners most often inherit risk — one ingredient can carry four different permissible claims across four markets.

Phase C — Build & Launch

The manufacturing and go-to-market work itself, once Phases A and B are settled. Vecura’'s role narrows here by design — the evidence work is done up front, and the build is the partner's craft.

The Core Value, Stated Plainly

Strip away the category and the workflow, and what Vecura sells an ODM/OEM partner is three things:

1. Compression. Weeks of literature review, regulatory archaeology, and supplier diligence, delivered in days.

2. Sourced honesty. Every claim cited and labeled; mixed results and gaps stated rather than smoothed over; nothing generated from memory and presented as fact.

3. Repeatability. Sleep used mechanism-first screening; beauty used claim-first screening; the next vertical will have its own logic. The seven use cases above don't change.

The boundaries are equally plain: Vecura does not approve claims, file regulatory paperwork, or forecast sales. Regulatory professionals file; the brand owns the claim; the partner owns the build.

Your Immediate Next Step

Pick one SKU in your pipeline — the one with the most regulatory exposure or the most expensive ingredient bet — and run it through the screening workflow. If the evidence package survives contact with the EU/Japan/Korea/US claim map, you have a launchable product. If it doesn't, you just saved a tooling budget. Either answer is worth days, not quarters.

All bracketed numbers reference sources verified during this engagement; formulation doses are published RCT/market ranges, not a validated protocol. Vecura does not approve claims, file regulatory paperwork, or forecast sales.